Abbott has recently received the US Food and Drug Administration nod to use its DBS device for treatment-resistant depression
A newly revealed mechanism by Weizmann Institute of Science of ketamine’s action on potassium channels in neurons may lead to improved therapies for depression
'Hello Skin' has been developed in collaboration with the IADVL (Indian Association of Dermatologists, Venereologists and Leprologists)
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of USFDA’s Priority Review action date
The icare4u program features a dedicated website, with comprehensive information about the diseases, videos with medical experts, and a social media community for patients and caregivers on Facebook and YouTube
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
It affects up to 10 per cent of women of reproductive age around the world
Jamnagar’s contributions towards wellness will get a global identity with WHO’s Global Centre for Traditional Medicine
Parkinson’s is not limited to old people, even youngsters can suffer from this disease
Subscribe To Our Newsletter & Stay Updated
